Norman Wolmark

Q: What Schools Are Affiliated With Norman Wolmark

Norman Wolmark is affiliated with the following schools: University of Vermont, University of Kentucky, University of Oxford, Riken, University of California, Los Angeles, University of Chicago, University of Siena, National Taiwan University, Yonsei University, Baylor University, McGill University, University of British Columbia, Allegheny University of the Health Sciences, University of Edinburgh, Oregon Health & Science University, Queen Mary University of London, University of Pittsburgh

Norman Wolmark's AcademicInfluence.com Rankings

Norman Wolmark

Physics

#3583

World Rank

#5056

Historical Rank

Cosmology

#92

World Rank

#97

Historical Rank

Astrophysics

#180

World Rank

#197

Historical Rank

physics Degrees

Download Badge

Physics

Norman Wolmark's Degrees

Bachelors Physics University of California, Berkeley
Masters Physics University of California, Berkeley
PhD Physics University of California, Berkeley

Why Is Norman Wolmark Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Norman Wolmark's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (2004) (5593)
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (5389)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) (2385)
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. (1998) (2102)
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. (1985) (2054)
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (1997) (1718)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. (1989) (1558)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. (2008) (1548)
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. (1989) (1427)
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. (2010) (1366)
Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. (1985) (1318)
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. (2002) (1271)
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2005) (1251)
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. (2002) (1239)
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. (2001) (1237)
Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer (2019) (1209)
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. (1995) (1131)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2003) (1080)
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. (1988) (1003)
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) (985)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. (2007) (954)
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. (2007) (909)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2006) (907)
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. (1996) (884)
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. (2009) (835)
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. (1993) (821)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. (2005) (776)
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. (2001) (751)
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. (1975) (704)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. (2005) (695)
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011) (685)
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. (2011) (680)
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. (1998) (674)
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. (1993) (656)
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. (1998) (637)
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. (2001) (637)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. (2004) (632)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe (1990) (593)
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. (2011) (576)
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. (2002) (574)
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. (2011) (557)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. (2010) (543)
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) (1999) (536)
Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. (2001) (518)
Significance of ipsilateral breast tumour recurrence after lumpectomy (1991) (517)
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. (1997) (512)
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. (2000) (506)
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. (2002) (492)
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2005) (488)
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. (1999) (469)
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. (2012) (457)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2018) (443)
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. (1994) (437)
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. (2006) (433)
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. (2012) (432)
The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. (1981) (431)
Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection (2010) (424)
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. (2004) (421)
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. (2009) (400)
Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. (1988) (399)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum (1997) (384)
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. (1989) (379)
Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. (1975) (365)
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. (2016) (362)
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. (2004) (359)
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. (2014) (354)
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials (2004) (348)
Pathobiology of preoperative chemotherapy (2002) (338)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. (2007) (332)
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. (2006) (331)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. (2013) (327)
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. (1997) (325)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. (2000) (322)
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. (2006) (317)
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. (2003) (313)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. (2008) (310)
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. (2010) (305)
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. (1990) (302)
Treatment of primary breast cancer with chemotherapy and tamoxifen. (1981) (296)
Effect of occult metastases on survival in node-negative breast cancer. (2011) (285)
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer (2012) (284)
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. (2010) (277)
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. (1983) (274)
Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (272)
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. (2001) (260)
Interstitial hypertension in human breast and colorectal tumors. (1992) (259)
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. (2002) (250)
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. (2009) (248)
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (247)
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. (2015) (245)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (2007) (232)
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial (2019) (230)
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. (1999) (226)
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. (2007) (226)
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and (1996) (226)
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (2011) (211)
Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. (1986) (209)
The Prognostic Value of the Modifications of the Dukes' C Class of Colorectal Cancer: An Analysis of the NSABP Clinical Trials (1986) (208)
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. (1990) (204)
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Association of tamoxifen and uterine sarcoma. (2002) (196)
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). (2017) (196)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 (2011) (191)
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. (2013) (184)
A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 (2005) (173)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. (2012) (166)
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. (2014) (165)
The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. (1983) (164)
The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. (1984) (164)
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (2004) (163)
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. (2013) (154)
Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. (2010) (154)
An Analysis of Survival and Treatment Failure Following Abdominoperineal and Sphincter‐saving Resection in Dukes' B and C Rectal Carcinoma: A Report of the NSABP Clinical Trials (1986) (152)
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. (1989) (151)
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. (2016) (149)
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. (2001) (144)
HER2 status and benefit from adjuvant trastuzumab in breast cancer. (2008) (144)
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. (2012) (142)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. (2019) (141)
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (137)
Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. (1999) (133)
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. (2015) (131)
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. (2011) (129)
A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. (2009) (129)
Eight-year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Lumpectomy with or without Irradiation in the Treatment of Breast Cancer (1989) (128)
NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial (2004) (125)
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. (2011) (122)
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. (2013) (121)
Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. (1987) (117)
Long-term tamoxifen citrate use and potential ocular toxicity. (1998) (114)
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer (2009) (114)
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. (1998) (112)
The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy (2003) (111)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. (2019) (110)
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. (2001) (110)
Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials (2010) (109)
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial (2008) (104)
Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials (2012) (103)
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy (2017) (103)
Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer (2005) (102)
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413. (2011) (100)
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. (2009) (99)
Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. (2004) (99)
Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. (2006) (97)
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. (2011) (95)
Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma (2005) (95)
Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. (2011) (91)
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. (2005) (89)
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. (2002) (88)
Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 (2003) (87)
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. (2010) (86)
Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01 (2012) (83)
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. (2003) (82)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. (2018) (81)
Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) (2006) (81)
Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. (2004) (80)
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. (2009) (80)
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer (2013) (79)
Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. (2001) (75)
Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (2007) (75)
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. (2009) (74)
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (74)
Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. (2007) (74)
Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials (2008) (72)
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. (2002) (72)
Lower-category benign breast disease and the risk of invasive breast cancer. (2004) (71)
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. (2010) (70)
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). (2006) (69)
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. (2007) (67)
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje (2016) (67)
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (66)
FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer (2008) (66)
Amenorrhea from breast cancer therapy--not a matter of dose. (2010) (66)
Tumor size and regional lymph node metastasis in colorectal cancer a preliminary analysis from the NSABP clinical trials (1983) (66)
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 (2013) (65)
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. (2010) (65)
Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23 (2004) (65)
Inhibitory effect of prolonged corynebacterium parvum and cyclophosphamide administration on the growth of established tumors (1975) (63)
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
Dukes' classification revisited. Findings from the national surgical adjuvant breast and bowel projects (protocol r‐01) (1989) (62)
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study (2013) (60)
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. (2010) (60)
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women (2008) (59)
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (58)
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. (2013) (58)
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. (2011) (57)
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. (2020) (56)
Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. (2006) (55)
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. (1999) (54)
The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice. (1974) (54)
Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. (1998) (54)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. (2019) (52)
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (2012) (52)
Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. (1986) (52)
Role of anthracyclines in the treatment of early breast cancer. (2009) (51)
Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. (2001) (50)
Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. (2003) (49)
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. (2004) (48)
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. (2020) (48)
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (2021) (48)
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. (2015) (47)
Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. (1998) (47)
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
Letrozole after tamoxifen for breast cancer--what is the price of success? (2003) (46)
Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. (2000) (46)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies (2019) (46)
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. (1989) (45)
10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (45)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. (2019) (44)
A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06 (2004) (44)
Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group (2009) (44)
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin (2007) (42)
Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer (2004) (42)
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. (2001) (42)
Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer (2019) (42)
Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. (1975) (39)
Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. (1994) (38)
An experimental study of the mechanical response of frozen biological tissues at cryogenic temperatures. (1996) (38)
CDX 2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer (2016) (37)
Long-term follow-up post-cryosurgery in a sheep breast model. (1999) (37)
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 (2017) (37)
Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. (2004) (36)
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 (2015) (36)
Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. (2020) (36)
NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (35)
The Prognostic Significance of Tumor Location and Bowel Obstruction in Dukes B and C Colorectal Cancer (1983) (34)
Endogenous sex hormone levels and breast cancer risk (1987) (34)
Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? (2007) (34)
Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. (2021) (33)
A comparison of stapled and handsewn anastomoses in patients undergoing resection for Dukes' B and C colorectal cancer (1986) (32)
Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). (1989) (32)
The use of tamoxifen and raloxifene for the prevention of breast cancer. (2009) (32)
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology (2018) (32)
Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum (2004) (32)
Status of adjuvant therapy for colorectal cancer. (1989) (31)
The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice. (1974) (31)
Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. (2012) (30)
Gross damage accumulation on frozen rabbit liver due to mechanical stress at cryogenic temperatures. (1997) (30)
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). (2017) (30)
Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0) (2007) (29)
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. (1981) (29)
Delayed severe hypertriglyceridemia from tamoxifen. (1997) (28)
Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early-phase trials. (2014) (28)
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). (2011) (27)
Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight‐year results from the national surgical adjuvant breast and bowel project B‐10 (1990) (27)
Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23 (2005) (27)
Conservative surgery: the American experience. (1986) (27)
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer (2008) (27)
Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (26)
The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth. (1976) (26)
Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
Neoadjuvant therapy for rectal cancer: Mature results from NSABP protocol R-04. (2014) (26)
Lumpectomy and axillary dissection for breast cancer: Surgical, pathological, and radiation considerations (1985) (25)
Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer (2008) (25)
Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2012) (25)
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. (2005) (25)
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (25)
A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (25)
S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (2011) (25)
Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial bre (2010) (25)
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. (2008) (25)
Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). (2006) (25)
An Association Between Postoperative Radiotherapy for Primary Breast Cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies and the Subsequent Appearance of Pleural Mesothelioma (2007) (24)
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. (2007) (24)
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results. (2019) (24)
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (24)
Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 (2012) (23)
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial (2017) (23)
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. (2021) (23)
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br (2016) (23)
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination (2019) (22)
Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed. (1974) (22)
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2011) (22)
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2020) (22)
The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (2011) (22)
Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism. (1976) (22)
Is boost therapy necessary in the treatment of DCIS (2008) (21)
Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer. (2014) (21)
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 (2015) (21)
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities (2013) (20)
Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. (2012) (20)
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. (2016) (20)
The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. (2006) (20)
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. (2020) (20)
A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. (2010) (20)
Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). (2012) (20)
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. (2016) (19)
The Prognostic Significance of Preoperative Carcinoembryonic Antigen Levels in Colorectal Cancer: Results from NSABP Clinical Trials (1984) (19)
Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. (2015) (19)
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 (2015) (18)
Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer (2015) (18)
A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. (2004) (17)
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. (2010) (17)
Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. (2006) (17)
Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity. (1976) (17)
Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. (2010) (16)
Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) → docetaxel (T) arm of NSABP B-30: Preliminary results (2005) (16)
Non-invasive breast carcinoma (2005) (16)
Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial. (2009) (16)
Adjuvant chemotherapy in colorectal cancer. (1985) (15)
Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. (2016) (15)
Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02) (2012) (15)
The effect of a growing tumor and its removal on the cytotoxicity of macrophages from cultured bone marrow cells. (1976) (14)
Further observations on the inhibition of tumor growth by corynebacterium parvum with cyclophosphamide. (1976) (14)
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study (2014) (14)
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. (2008) (14)
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (14)
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2018) (13)
Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (13)
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (13)
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial (2021) (13)
Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. (2021) (13)
Predictive value of microsatellite instability-high remains controversial. (2007) (13)
Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer (2015) (12)
Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. (2011) (12)
Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. II. Effect of cortisone acetate. (1976) (12)
Abstract S2-05: 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients (2013) (12)
A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. (2012) (12)
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results. (2021) (12)
Minimal breast cancer: advance or anachronism? (1985) (12)
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (2010) (12)
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. (2021) (12)
A compact cryosurgical apparatus for minimally invasive procedures. (1997) (12)
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer (2020) (11)
Development of a cryosurgical technique for breast malignancies (1999) (11)
Sam Wieand, PhD (2006) (11)
Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. (2014) (10)
IS TAMOXIFEN A RISK FACTOR FOR RETINAL VASO-OCCLUSIVE DISEASE? (2005) (10)
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study (2020) (10)
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. (2009) (10)
Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 (2015) (10)
Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04. (2005) (10)
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2008) (9)
Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) (2013) (9)
Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). (2019) (9)
Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24 (2007) (9)
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response (2020) (9)
The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis (2005) (9)
Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. (2021) (8)
NSABP Protocol B-06: A randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer — Results after 15 years of follow-up (1998) (8)
NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. (2020) (8)
NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer. (2017) (8)
Conditional survival for patients with colon cancer: An analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials C-03 through C-06. (2006) (8)
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 (2017) (8)
Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). (2017) (8)
Results of Investigations with Corynebacterium parvum in an Experimental Animal System (1975) (8)
Surgery in the primary treatment of breast cancer (2005) (8)
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). (2020) (7)
Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (2019) (7)
The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. (2006) (7)
Future directions in the adjuvant treatment of colon cancer. (1997) (7)
Limited surgical management for primary breast cancer: A commentary on the NSABP reports (1985) (7)
The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. (1992) (7)
Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03 (2005) (7)
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). (2014) (7)
Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. (2019) (7)
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report (2020) (7)
Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2. (1992) (7)
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. (2019) (6)
Effect of body mass index on outcomes in patients with Dukes B and C colon cancer: An analysis of NSABP randomized trials (2005) (6)
NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. (2013) (6)
Adjuvant therapy in primary breast cancer. (1985) (6)
Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B-09 (1985) (6)
Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
P39 08 TP – INTERSTITIAL HYPERTENSION IN HUMAN PRIMARY AND METASTATIC TUMORS (1991) (6)
Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study (2019) (6)
Adjuvant therapy for colorectal cancer: the NSABP clinical trials. (1988) (6)
Systemic Adjuvant (Combined Modality) Therapy in the Treatment of Primary Breast Cancer (1977) (5)
Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy. (2020) (5)
Correlations Among p 53 , Her-2 / neu , and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer : Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas 1 (2000) (5)
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili (2021) (5)
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. (2020) (5)
Laminated Marlex-methyl methacrylate prosthesis for massive chest wall resection. (1980) (5)
Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC) (2007) (5)
Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials (2005) (5)
PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. (2011) (5)
Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer. (2019) (5)
Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database. (2018) (5)
Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials (1985) (5)
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield (1993) (5)
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metas (2021) (5)
NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (5)
Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. (2010) (5)
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer. (2018) (5)
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial. (2018) (5)
OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43. (2011) (4)
Indications for breast-preserving surgery and adjuvant therapy in early breast cancer. (1994) (4)
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29 (2015) (4)
EVALUATION OF POST CRYOSURGERY INJURY IN A SHEEP BREAST MODEL USING THE VITAL STAIN 2,3,5-TRIPHENYLTETRAZOLIUM CHLORIDE (1998) (4)
Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. (2021) (4)
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (4)
Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04. (2012) (4)
NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. (2021) (4)
Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2008) (4)
Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP (2009) (4)
Bernard Fisher, 1918-2019. (2020) (4)
Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 (2012) (4)
Pattern of regional failure in patients with breast cancer treated by lumpectomy, breast radiation +/− chemotherapy and/or tamoxifen with no regional radiation: results from 10 NSABP randomized trials (2003) (4)
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice (2021) (4)
The current status of systemic adjuvant therapy in the management of primary breast cancer. (1981) (4)
A comparison of quality of life in colon cancer patients receiving adjuvant uracil/ftorafur + leucovorin versus 5-fluorouracil + leucovorin in NSABP C-06 (2005) (4)
Current Activities of the Coalition of Cancer Cooperative Groups. (2018) (4)
NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx). (2013) (4)
Chemotherapy and tamoxifen for breast cancer. (1981) (3)
Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002. (2016) (3)
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9. (2014) (3)
Improved lymphocyte cytotoxicity against murine renal cell carcinoma. (1992) (3)
Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. (2016) (3)
A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002. (2019) (3)
Abstract OT1-2-01: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) (2012) (3)
Tamoxifen a nd C hemotherapy f or A xillary N ode-Negative, Estrogen R eceptor-Negativ e B reast C ancer: F indings F rom National S urgical A djuvant B reast a nd B owel P roject B -23 (2001) (3)
NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). (2012) (3)
A comparison of two and three years of adjuvant tamoxifen. (1989) (3)
NRG Oncology research opportunities within the new National Clinical Trials Network. (2014) (3)
Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2020) (3)
Abstract S4-9: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score (2010) (3)
Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (3)
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) (3)
Overview docetaxel at the 2005 San Antonio Breast Cancer Symposium (2006) (2)
Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis (2020) (2)
Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy (2016) (2)
Comparative effectiveness of sphincter-sparing surgery (SSS) versus abdomino-perineal resection (APR) in rectal cancer: Patient-reported outcomes (PROs) from NSABP R-04. (2012) (2)
Mucosal field change in colorectal cancer (1987) (2)
The Impact of Radiation Therapy on Lymphedema Risk and the Agreement Between Subjective and Objective Lymphedema Measures: NSABP B-32 Secondary Data Analysis (2014) (2)
The 12-Gene Colon Cancer Recurrence Score (RS) Predicts Recurrence in Stage II and III Colon Cancer Patients Treated with 5FU/LV (FU) and 5FU/LV + Oxaliplatin (FU + OX): Validation in NSABP C07 (2012) (2)
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab (2021) (2)
Abstract OT2-3-02: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) (2013) (2)
Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver. (2010) (2)
A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis. (2013) (2)
Predictive Factors for Positive Non-Sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32. (2009) (2)
Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial. (2017) (2)
Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. (2012) (2)
P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33 (2007) (2)
Abstract P3-10-04: The fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in the neoadjuvant setting in NSABP clinical trial FB-7 (2019) (2)
Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial (2007) (2)
Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 (2017) (2)
Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells. (1980) (2)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies. (2019) (2)
Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab (2015) (2)
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). (2017) (2)
Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (2012) (2)
Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform. (2017) (2)
INFLAMMATORY CELL INFILTRATE IN A RESPONDING METASTATIC NODULE AFTER ADOPTIVE TRANSFER OF IN VITRO SENSITIZED (IVS) T CELLS AND SYSTEMIC INTERLEUKIN-2 (1992) (2)
Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07. (2016) (2)
Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32. (2011) (2)
Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells. (1979) (2)
Quality of life in breast cancer patients receiving sentinel-node (SN) biopsy alone or with axillary dissection (AD): Results from NSABP Protocol B-32 (2008) (2)
Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (2015) (2)
Abstract OT2-02-03: NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer (2020) (2)
Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 (2013) (2)
Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 (2020) (1)
Relationship between number of lymph node dissected and the risk of axillary/supraclavicular failure in patients with breast cancer treated by mastectomy and chemotherapy (+/- tamoxifen) without radiation: results from five NSABP trials (2002) (1)
Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2019) (1)
The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment (2007) (1)
Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database. (2018) (1)
Rethinking the role of nodal status in TNM staging of node-positive breast cancer (2007) (1)
P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen (2015) (1)
Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. (2016) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. (2011) (1)
Stapled Baker type anastomosis for low anterior resections. (1990) (1)
Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
Dose intensity comparison of African-American and white patients in NSABP breast treatment trials of postoperative doxorubicin and cyclophosphamide. (2006) (1)
The Credentialing Process for the NSABP B-51/RTOG 1304 Phase 3 Randomized Clinical Trial (2014) (1)
NRG-GI002: A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer. (2018) (1)
Provocative optimism in the treatment of early stage disease. (2005) (1)
Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. (2011) (1)
Abstract P6-07-06: Patterns of locoregional failure in the CALOR (Chemotheraphy as Adjuvant for Locally Recurrent Breast Cancer) Trial (2012) (1)
Abstract S5-1: Prospective Outcomes for Patients with Micro-Metastases and Macro-Metastases In Sentinel Nodes: NSABP B-32 Sentinel Node Trial (2010) (1)
An Update of the Credentialing Process for the NRG Oncology NSABP B-51 / RTOG 1304 Phase 3 Randomized Clinical Trial (2015) (1)
DCIS: evidence from radomized trials (2003) (1)
478 Prognostic Significance of pAKT Plus Estrogen Receptor Status in Adjuvant Cytotoxic Treatment of Breast Cancer (2012) (1)
Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32. (2011) (0)
IL-2 Adjuvant Therapy of Colorectal Cancer : the NSABP Experience (2006) (0)
Prolonging Tamoxifen Therapy for Primary Breast Cancer (2020) (0)
Comparison of self-reported outcomes with arm functional measurements in early breast cancer patients undergoing nodal biopsy in NSABP Protocol B-32 (2005) (0)
CONSIDERATIONS IN THE DEVELOPMENT AND VALIDATION OF GENOMIC TESTS FOR CANCER RECURRENCE AND TREATMENT BENEFIT (2010) (0)
Adjuvant Therapy for Breast Cancer: Where We Are, Where We're Headed (2008) (0)
NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR). (2019) (0)
Mammographic density and obesity as risk factors for invasive breast cancer following ductal carcinoma in situ (DCIS) (2003) (0)
Abstract P2-16-26: Mixed invasive ductal and lobular carcinoma (IDC/L) behaves similarly to invasive lobular carcinoma (ILC) with regard to neoadjuvant chemotherapy response and metastatic dissemination (2020) (0)
NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC). (2020) (0)
Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2. (2019) (0)
Abstract PS7-15: Mixed invasive ductal lobular carcinomas (mDLC) are clinically more similar to invasive lobular carcinoma (ILC) than to invasive ductal carcinoma (IDC) (2021) (0)
Augmentation of cell mediated cytotoxicity (cmc) in tumor bearing mice following transfer of tumor sensitized spleen cells (tssc). Abstr. (1981) (0)
Abstract P6-10-03: The contribution of common genetic variation to breast cancer risk among women receiving tamoxifen or raloxifene within the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 trials (2015) (0)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer (2019) (0)
TAILORx Update (2019) (0)
Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08. (2021) (0)
KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) (0)
Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system (2008) (0)
A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. (2012) (0)
Abstract 3407: Development of a chemokine signature identifying dMMR patients (pts) with poor prognosis (2019) (0)
Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07 (2009) (0)
Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes. (1987) (0)
A Pilot Clinical Trial to Assess Percutaneous Segmental Mastectomy in Women with Malignant Tumors < or = 1.0 Centimeter (1999) (0)
Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases. (1975) (0)
Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience (2002) (0)
Title Cancer survivorship research : the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group Permalink (2009) (0)
Abstract 4727: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression (2011) (0)
Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database. (2018) (0)
A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (0)
P1-06-15: A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics. (2011) (0)
The significance of regional lymph node cell mediated cytotoxicity in the response of a murine adenocarcinoma to chemoimmunotherapy. Abstr. (1983) (0)
Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less (2002) (0)
Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer (2003) (0)
177PRECURRENCE SCORE AND QUANTITATIVE ER EXPRESSION PREDICTS LATE DISTANT RECURRENCE RISK IN ER+ BC AFTER FIVE YEARS OF TAMOXIFEN. (2014) (0)
P39 13 TP – GEOMETRIC RESISTANCE AND VASCULAR ARCHITECTURE OF HUMAN TUMORS (1991) (0)
Course announcement (2005) (0)
Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
Tumor metastasis of mammary carcinoma to the lung reflected in an in vitro chemotaxis assay of bone marrow cells from c3h mice. Abstr. (1981) (0)
Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer (2011) (0)
P3-13-01: Boost Radiation Therapy Not of Value in Reducing IBTR of Invasive or Noninvasive Breast Cancers for Patients with DCIS: Results from the NSABP B-24 Trial. (2011) (0)
Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD) (2017) (0)
American Society of Colon and Rectal Surgeons 95th Annual Convention Podium and Poster Abstracts June 9–14, 1996 Seattle, Washington (1996) (0)
Metastatic behavior of mixed invasive ductal lobular carcinoma (mIDC/ILC). (2020) (0)
Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials. (2020) (0)
Abstract ML1: The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer (2016) (0)
Editorial: Adjuvant chemotherapy in colorectal cancer. (1976) (0)
Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy (2019) (0)
Reply to S. Mahesh (2012) (0)
Reply to R. Glynne-Jones et al (2010) (0)
Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer (2010) (0)
Book reviews (2005) (0)
Efficacy of Oxaliplatin on Overall and Disease-Free Survival (2008) (0)
Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study (2019) (0)
Demographic characteristics and quality of life factors among the participants of the breast cancer prevention trial (1998) (0)
Progress in carcinoma of the breast—Introduction (1985) (0)
Cellular cytotoxicity in tumor-bearing mice after transfer of normal or tumor-sensitized lymphoid cells. (1980) (0)
Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
The Use of Tramoxifen and Roloxifene for the Prevention of Breast Cancer (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Norman Wolmark?

Norman Wolmark is affiliated with the following schools:

University of Vermont
University of Kentucky
University of Oxford
Riken
University of California, Los Angeles
University of Chicago
University of Siena
National Taiwan University
Yonsei University
Baylor University
McGill University
University of British Columbia
Allegheny University of the Health Sciences
University of Edinburgh
Oregon Health & Science University
Queen Mary University of London
University of Pittsburgh

Norman Wolmark's Academic­Influence.com Rankings

Norman Wolmark's Degrees

Why Is Norman Wolmark Influential?

Norman Wolmark's Published Works

Published Works

What Schools Are Affiliated With Norman Wolmark?

Norman Wolmark's AcademicInfluence.com Rankings